We are live on
!
Find out more
PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+21.83%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$115M
AUM Growth
+$8.7M
(+8.2%)
Cap. Flow
-$1.24M
Cap. Flow
% of AUM
-1.08%
Top 10 Holdings %
Top 10 Hldgs %
36.88%
Holding
101
New
4
Increased
12
Reduced
48
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$912K |
| 2 |
Intel
INTC
|
+$677K |
| 3 |
RingCentral
RNG
|
+$354K |
| 4 |
TELA Bio
TELA
|
+$245K |
| 5 |
Inuvo
INUV
|
+$202K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rockwell Medical
RMTI
|
+$747K |
| 2 |
3M
MMM
|
+$529K |
| 3 |
BIOL
Biolase, Inc.
BIOL
|
+$430K |
| 4 |
AUGX
Augmedix, Inc. Common Stock
AUGX
|
+$332K |
| 5 |
Advanced Micro Devices
AMD
|
+$229K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 55.16% |
| 2 | Technology | 24.2% |
| 3 | Industrials | 9.3% |
| 4 | Communication Services | 6.4% |
| 5 | Consumer Staples | 2.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AUGX
1
DELISTED
Augmedix, Inc. Common Stock
AUGX
| $7.41M | 6.46% |
1,540,993
-95,850
| -6% | -$332K |
|
2
Eli Lilly
LLY
$1.02T
| $6.12M | 5.33% |
13,041
-100
| -0.8% | -$41.9K |
|
3
Idexx Laboratories
IDXX
$42.2B
| $5.43M | 4.73% |
10,805
| – | – |
|
4
Microsoft
MSFT
$3.71T
| $5.22M | 4.55% |
15,326
| – | – |
|
5
NeoGenomics
NEO
$2.23B
| $3.16M | 2.75% |
196,500
-500
| -0.3% | -$8.24K |
|
6
Alphatec Holdings
ATEC
$1.46B
| $3.13M | 2.73% |
174,117
-6,650
| -4% | -$104K |
|
7
Veracyte
VCYT
$3.42B
| $3.09M | 2.69% |
121,330
-550
| -0.5% | -$13.3K |
|
8
Natera
NTRA
$47.3B
| $3.03M | 2.64% |
62,200
-500
| -0.8% | -$25.5K |
|
9
Perion Network
PERI
$366M
| $2.97M | 2.59% |
96,885
-1,300
| -1% | -$44.6K |
|
10
Abbott
ABT
$187B
| $2.77M | 2.41% |
25,380
-1,000
| -4% | -$107K |
|
11
Axogen
AXGN
$2.6B
| $2.73M | 2.38% |
298,890
-10,600
| -3% | -$98.8K |
|
|
12
Advanced Micro Devices
AMD
$780B
| $2.65M | 2.31% |
23,234
-2,200
| -9% | -$229K |
|
13
Digi International
DGII
$2.63B
| $2.63M | 2.3% |
66,858
-3,025
| -4% | -$104K |
|
14
LeMaitre Vascular
LMAT
$1.84B
| $2.38M | 2.08% |
35,436
-1,000
| -3% | -$61K |
|
15
Ooma
OOMA
$637M
| $2.18M | 1.9% |
145,650
-750
| -0.5% | -$9.87K |
|
16
QuickLogic
QUIK
$197M
| $2.08M | 1.81% |
226,463
-6,000
| -3% | -$38.1K |
|
17
Tactile Systems Technology
TCMD
$495M
| $2.08M | 1.81% |
83,350
-884
| -1% | -$18.4K |
|
|
CTLP
18
DELISTED
Cantaloupe
CTLP
| $2.07M | 1.81% |
260,350
-14,000
| -5% | -$90.7K |
|
|
STRM
19
DELISTED
Streamline Health Solutions
STRM
| $1.96M | 1.71% |
102,883
-1,140
| -1% | -$27.4K |
|
|
20
TELA Bio
TELA
$36.9M
| $1.93M | 1.68% |
190,500
+24,000
| +14% | +$245K |
|
21
Magnite
MGNI
$3.46B
| $1.82M | 1.59% |
133,325
| – | – |
|
22
Perspective Therapeutics
CATX
$357M
| $1.79M | 1.56% |
267,464
-7,500
| -3% | -$45.5K |
|
23
Pfizer
PFE
$162B
| $1.77M | 1.55% |
48,341
-1,000
| -2% | -$38.9K |
|
|
AKTS
24
DELISTED
Akoustis Technologies Inc
AKTS
| $1.72M | 1.49% |
539,250
-10,000
| -2% | -$30.7K |
|
|
PFIE
25
DELISTED
Profire Energy, Inc
PFIE
| $1.67M | 1.45% |
1,353,256
-50,960
| -4% | -$63.2K |
|
Similar funds
AA
WA
AC
BCVI
SWM
HAP
RHIG
CWM
Perkins Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Perkins Capital Management held 101 positions worth $115M, up 8.2% from $106M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Perkins Capital Management's Q2 2023 filing shows 4 new, 12 increased, 48 reduced and 4 closed positions. Its largest new stake was Baxter International: 20,934 shares worth $954K. The largest sale was Rockwell Medical, an estimated $747K.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 58% a quarter earlier, followed by Technology and Industrials.
- Perkins Capital Management's largest Q2 2023 buy was Baxter International: 20,934 shares worth $954K.
- Perkins Capital Management added most to TELA Bio in Q2 2023, an estimated $245K increase.
- Perkins Capital Management's biggest Q2 2023 reduction was Rockwell Medical, cutting an estimated $747K.
- Perkins Capital Management fully exited 3M in Q2 2023, selling an estimated $529K.
- Perkins Capital Management's ten largest holdings make up 37% of its $115M portfolio in Q2 2023.
- Perkins Capital Management opened 4 new positions and closed 4 in Q2 2023.
- Perkins Capital Management's portfolio value rose 8.2% quarter-over-quarter to $115M.
Based on Perkins Capital Management's 13F filing for Q2 2023, filed 21 Jul 2023.